Compare Sanofi SA (SNY) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Yum China Holdings Inc — how do they compare? Sanofi SA trades at $40.07 (market cap $95.18B), while Yum China Holdings Inc trades at $42.92 (market cap $14.11B). The key difference: Sanofi SA is far larger — about 6.7× Yum China Holdings Inc's market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and Yum China Holdings Inc for 77 Days on average.
| SNY | YUMC | |
|---|---|---|
Market Cap | $95.18B | $14.11B |
Volume | 2,995,646 | 2,350,650 |
Sector | Health | Consumer Cyclical |
52-Week High | $52.34 | $57.95 |
52-Week Low | $39.51 | $39.98 |
Typical Hold Time | 94 Days | 77 Days |
Enterprise Value | $114.48B | $15.02B |
Dividend Yield | 6.01% | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
YUMC trades at $41.78, up 2.78% today, but technical indicators signal a bearish trend with strong sell signals from moving averages. Fundamentally, the company shows steady revenue growth, reaching $11.80B in 2025, with consistent earnings beats in recent quarters. Recent developments include the acquisition of Pizza Hut brand ownership in mainland China and expansion of Pizza Hut Burger Bars to 300 locations.
The outlook is mixed: strong analyst consensus (73.68% buy ratings) and a projected 25.63% upside suggest value, but bearish technicals and competitive pressures pose risks. Investors should weigh solid fundamentals against near-term price volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
